Table 1.
Baseline demographics and outcome variables
|
Placebo |
Minocycline |
||||
|---|---|---|---|---|---|
| n | Mean (SD) | n | Mean (SD) | ||
| Sex | |||||
| Male | 73 | .. | 77 | .. | |
| Female | 30 | .. | 27 | .. | |
| Age, years | 101 | 25·7 (5·1) | 103 | 25·5 (5·2) | |
| PANSS score | |||||
| Negative symptom subscale score | 104 | 16·8 (5·5) | 103 | 17·7 5·9) | |
| Positive symptom subscale score | 104 | 17·3 (5·3) | 103 | 16·3 (4·1) | |
| Total PANSS score | 103 | 69·3 (15·4) | 103 | 67·1 (13·2) | |
| CDSS score | 103 | 5·5 (5·0) | 103 | 5·2 (4·3) | |
| GAF score | 103 | 56·2 (11·6) | 102 | 55·5 (9·1) | |
| Weight, kg | 101 | 86·8 (25·3) | 97 | 82·6 (19·6) | |
| Body-mass index | 101 | 28·7 (7·6) | 96 | 27·1 (6·2) | |
| Processing speed | 91 | 52·8 (16·8) | 95 | 58·0 (16·7) | |
| Current IQ | 100 | 89·2 (15·9) | 101 | 91·2 (14·0) | |
| Premorbid IQ | 98 | 95·4 (19·8) | 100 | 97·7 (1·7) | |
| Medial prefrontal cortex grey-matter volume (cc) | |||||
| Left grey-matter volume | 88 | 5·7 (0·8) | 94 | 5·6 (0·7) | |
| Right grey-matter volume | 88 | 4·6 (0·7) | 94 | 4·6 (5·8) | |
| N-back BOLD activation (% change) | |||||
| 1-back plus 2-back vs 0-back | 88 | 0·12% (1·25) | 94 | −0·02% (1·48) | |
| 2-back vs 1-back | 88 | 0·10% (1·23) | 94 | −0·04% (1·54) | |
| Cytokine IL-6, pg/mL | 100 | 0·84 (0·64) | 101 | 0·69 (0·46) | |
| hs-CRP, mg/L | 100 | 3·83 (5·45) | 101 | 3·08 (3·82) | |
PANSS=Positive and Negative Syndrome Scales. CDSS=Calgary Depression Scale for Schizophrenia. GAF=Global Assessment of Functioning. IQ=intelligence quotient. BOLD=blood-oxygen-level-dependent imaging. IL-6=interleukin 6. hs-CRP=high-sensitivity C-reactive protein.